A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3555-3561

  Frankel, Arthur E ^a,e   Fleming, Donald R ^b   Hall, Philip D ^c   Powell, Bayard L ^a   Black, Jennifer H ^a   Leftwich, Carole ^a   Gartenhaus, Ronald ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b Medical Center of Vincennes   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DENILEUKIN DIFTITOX; FLUDARABINE; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ANAPHYLAXIS; ANOREXIA; ARTICLE; ASTHENIA; BACTEREMIA; BONE MARROW BIOPSY; CANCER PATIENT; CANCER STAGING; CAPILLARY LEAK SYNDROME; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GUILLAIN BARRE SYNDROME; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW CELLS; DIPHTHERIA TOXIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; VIDARABINE;

EID: 0141679441     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zent, C. S., Kyasa, M. J., Evans, R., and Schichman, S. A. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer (Phila.), 92: 1325-1330, 2001.
2. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S., and Rai, K. R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87: 4990-4997, 1996.
3. Frankel, A. E., Powell, B. L., Vallera, D. A., and Neville, D. M. Chimeric fusion proteins: diphtheria toxin-based. Curr. Opin. Investig. Drugs, 2: 1294-1301, 2001.
4. Williams, D. P., Snider, C. E., Strom, T. B., and Murphy, J. R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem., 265: 11885-11889, 1990.
5. Bamborough, P., Hedgecock, C. J., and Richards, W. G. The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Structure (Lond.), 2: 839-851, 1994.
6. Tsilivakos, V., Tsapis, A., Kokolyris, S., Iliakis, P., Perraki, M., and Georgoulias, V. Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia (Baltimore), 8: 1571-1578, 1994.
7. Falnes, P. O., and Sandvig, K. Penetration of protein toxins into cells. Curr. Opin. Cell. Biol., 12: 407-413, 2000.
8. Re, G. G., Waters, C., Poisson, L., Willingham, M. C., Sugamura, K., and Frankel, A. E. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res., 56: 2590-2595, 1996.
9. Bacha, P. A., Forte, S. E., McCarthy, D. M., Estis, L., Yamada, G., and Nichols, J. C. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. J. Cancer, 49: 96-101, 1991.
10. LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., Reuben, J., and Nichols, J. C. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood, 91: 399-405, 1998.
11. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., and Nichols, J. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol., 19: 376-388, 2001.
12. Foss, F. M., Bacha, P., Osann, K. E., Demierre, M. F., Bell, T., and Kuzel, T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma, 1: 298-302, 2001.
13. Hall, P. D., Virella, G., Willoughby, T., Atchley, D. H., Kreitman, R. J., and Frankel, A. E. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a Phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin. Immunol., 100: 191-197, 2001.
14. Doney, K. C., Chauncey, T., and Appelbaum, F. R. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant., 29: 817-823, 2002.
15. Perkins, J. G., Flynn, J. M., Howard, R. S., and Byrd, J. C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer (Phila.), 94: 2033-2039, 2002.
16. Thornton, P. D., Hamblin, M., Treleaven, J. G., Matutes, E., Lakhani, A. K., and Catovksy, D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk. Lymphoma, 34: 167-170, 1999.
17. Hertler, A. A., Schlossman, D. M., Borowitz, M. J., Blythman, H. E., Casellas, P., and Frankel, A. E. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int. J. Cancer, 43: 215-219, 1989.
18. Gorgun, G., and Foss, F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 100: 1399-1403, 2002.
19. Nakase, K., Kita, K., Shirakawa, S., Tanaka, I., and Tsudo, M. Induction of cell surface interleukin 2 receptor alpha chain expression on non-T lymphoid leukemia cells. Leuk. Res., 18: 855-859, 1994.
20. Decker, T., Hipp, S., Kreitman, R. J., Pastan, I., Peschel, C., and Licht, T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood, 99: 1320-1326, 2002.
21. Digel, W., Schmid, M., Heil, G., Conrad, P., Gillis, S., and Porzsolt, F. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood, 78: 753-759, 1991.
22. Trentin, L., Zambello, R., Agostini, C., Enthammer, C., Cerutti, A., Adami, F., Zamboni, S., and Semenzato, G. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 84: 4249-4256, 1994.
23. Pedersen, I. M., Kitada, S., Leoni, L. M., Zapata, J. M., Karras, J. G., Tsukada, N., Kipps, T. J., Choi, Y. S., Bennett, F., and Reed, J. C. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood, 100: 1795-1801, 2002.
24. Tsukada, N., Burger, J. A., Zveifler, N. J., and Kipps, T. J. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood, 99: 1030-1037, 2002.
25. Burger, J. A., and Kipps, T. J. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk. Lymphoma, 43: 461-466, 2002.
26. Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., Grillo-Lopez, A. J., Rosenberg, J., Kunkel, L., and Flinn, I. W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol., 19: 2153-2164, 2001.